Incidensen af klinisk respons i uge 16 var efter den første (n=287), anden (n=123) og tredje (n=30) behandling henholdsvis 85, 0%, 86, 2% og 80%.
Incidence of clinical response at week 16 following the first (n=287), second (n=123) and third (n=30) treatments was 85.0%, 86.2% and 80% respectively.